Back to top
more

Alnylam Pharmaceuticals (ALNY)

(Delayed Data from NSDQ)

$243.00 USD

243.00
3,246,489

-4.00 (-1.62%)

Updated Jun 28, 2024 04:00 PM ET

After-Market: $243.01 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

Alnylam Pharmaceuticals, Inc. [ALNY]

Reports for Purchase

Showing records 281 - 300 ( 414 total )

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 281

07/16/2012

Company Report

Pages: 8

Price: 24.95

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 282

07/11/2012

Company Report

Pages: 7

Hemophilia Program Takes Shape, Bolstered by GalNac Delivery Platform

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 25.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 283

07/11/2012

Daily Note

Pages: 3

Hemophilia Program Takes Shape, Bolstered by GalNac Delivery Platform

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 284

07/10/2012

Company Report

Pages: 5

Upcoming TTR-02 Data Should Provide Near-Term Catalyst to ALNY Shares

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 285

06/12/2012

Daily Note

Pages: 3

Pre-Clinical Data from ALNY Signals Growing Belief in siRNA Approaches Addressing Anemia

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 286

06/12/2012

Company Report

Pages: 4

Pre-Clinical Data from ALNY Signals Growing Belief in siRNA Approaches Addressing Anemia

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 287

05/30/2012

Daily Note

Pages: 3

Phase II Data Breathes Life into ALN-RSV01, For Now

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 288

05/30/2012

Company Report

Pages: 4

Phase II Data Breathes Life into ALN-RSV01, For Now

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 289

05/29/2012

Company Report

Pages: 3

Additional Details from Phase II Trial of REGN727 and Plans for Phase III Released

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 290

05/29/2012

Daily Note

Pages: 3

Additional Details from Phase II Trial of REGN727 and Plans for Phase III Released

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 291

05/25/2012

Company Report

Pages: 4

Unmet Need in TTR Overcomes Trial Deficiencies:

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 292

05/25/2012

Daily Note

Pages: 3

Unmet Need in TTR Overcomes Trial Deficiencies:

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 293

05/17/2012

Industry Report

Pages: 3

2012 ASCO PLANNER

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 294

05/04/2012

Company Report

Pages: 8

Solid Quarter as Controls Costs and Sets Portfolio Priorities

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 25.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 295

05/04/2012

Daily Note

Pages: 3

Solid Quarter as Controls Costs and Sets Portfolio Priorities

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 296

05/04/2012

Company Report

Pages: 8

Price: 24.95

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 297

04/23/2012

Daily Note

Pages: 3

Releases Updated Results from ALN-PCS Phase - Trial

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 298

04/23/2012

Company Report

Pages: 5

Releases Updated Results from ALN-PCS Phase I Trial

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 299

04/12/2012

Daily Note

Pages: 5

Preview of New PCSK9 Data at ATVB Next Week

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party

Company: Alnylam Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 300

04/12/2012

Daily Note

Pages: 3

Preview of New PCSK9 Data at ATVB Next Week

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 10.00

Research Provided by a Third Party